Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Giannis Mountzios, Jordi Remón, Lizza E.L. Hendriks, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 664-677
Closed Access | Times Cited: 106

Showing 1-25 of 106 citing articles:

Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Bilan Wang, Shiqi Hu, Yan Teng, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 81
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Mı́riam Molina-Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 48
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
Giuseppe Luigi Banna, Mohd Ali Hassan, Alessio Signori, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e246837-e246837
Open Access | Times Cited: 29
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan Spicer, Tina Cascone, Murry W. Wynes, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1373-1414
Open Access | Times Cited: 25
Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy
Yuzhu Hu, Wen Nie, Liang Lyu, et al.
ACS Nano (2024) Vol. 18, Iss. 4, pp. 3295-3312
Closed Access | Times Cited: 16
Triune Nanomodulator Enables Exhausted Cytotoxic T Lymphocyte Rejuvenation for Cancer Epigenetic Immunotherapy
Junhua Li, Quan Zhao, Nan Zhang, et al.
ACS Nano (2024) Vol. 18, Iss. 20, pp. 13226-13240
Closed Access | Times Cited: 16
Patient‐derived xenograft model in cancer: establishment and applications
Ao Gu, Jiatong Li, Mengyao Li, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access | Times Cited: 5
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104190-104190
Open Access | Times Cited: 25
Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer
Ming Gu, Yang Liu, Wenhui Zheng, et al.
Seminars in Cancer Biology (2024) Vol. 106-107, pp. 43-57
Closed Access | Times Cited: 11
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
Minghua Xiang, Huayi Li, Yuanyuan Zhan, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
Chris Abbosh, Darren Hodgson, Gary J. Doherty, et al.
Trends in cancer (2024) Vol. 10, Iss. 7, pp. 643-654
Open Access | Times Cited: 9
Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy
Qiaohong Geng, Peifu Jiao
Molecules (2024) Vol. 29, Iss. 2, pp. 454-454
Open Access | Times Cited: 8
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Elena Catanzaro, Manuel Beltrán‐Visiedo, Lorenzo Galluzzi, et al.
Cellular and Molecular Immunology (2024)
Open Access | Times Cited: 8
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Lorenzo Foffano, Elisa Bertoli, Martina Bortolot, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 583-583
Open Access | Times Cited: 1
Construction of a novel disulfidptosis-related lncRNAs signature for prognosis prediction and anti-tumor immunity in laryngeal squamous cell carcinoma
Min Zhang, Qing Sun, Zhijin Han, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e30877-e30877
Open Access | Times Cited: 7
A computer-aided, heterodimer-based “triadic” carrier-free drug delivery platform to mitigate multidrug resistance in lung cancer and enhance efficiency
Liyan Yang, Yingying Zhang, Yuxin Lai, et al.
Journal of Colloid and Interface Science (2024) Vol. 677, pp. 523-540
Closed Access | Times Cited: 7
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
A. Nuccio, Giuseppe Viscardi, Fabio Salomone, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113404-113404
Closed Access | Times Cited: 15
Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer
Christian Rolfo, Alessandro Russo
Annals of Oncology (2024) Vol. 35, Iss. 2, pp. 147-149
Open Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer
Zixuan Li, Huichan Xue, Jinsong Li, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 4
Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer
Ran Ni, Zhiming Hu, Ran Tao
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117430-117430
Open Access | Times Cited: 4
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
Daniele Marinelli, A. Nuccio, Alessandro Di Federico, et al.
Journal of Thoracic Oncology (2024)
Closed Access | Times Cited: 4
Self-assembly of multi-arm star PEG containing TXA9 into nanoparticle for the efficient chemotherapy of NSCLC
Qilong Wang, Zhe Liu, Jiale Yao, et al.
Drug Delivery and Translational Research (2025)
Closed Access
Integrative analysis of single-cell and transcriptome sequencing with experimental validation reveals PKHD1L1 as a novel biomarker in lung adenocarcinoma
Xiangqian Zhang, Jie Wang, Hong Su, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top